Sort   by:  
 Page size 
UnknownDoes Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Not available
S-EPMC5070573 | biostudies-literature
UnknownIntrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
Not available
S-EPMC3732011 | biostudies-literature
TranscriptomicsMGMT-STP27 methylation status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Homo sapiens 
2013-08-26 | E-GEOD-48462 | biostudies-arrayexpress
TranscriptomicsMGMT-STP27 methylation status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas; A report from EORTC study 26951
Purpose: The long-term follow-up results from the EORTC-26951 trial showed that the addition of PCV after radiotherapy increases survival in anaplastic oligodendrogliomas/oligoastrocytomas (AOD/AOA). However, some patients appeared to benefit more from PCV treatment than others. Experimental Design...
ORGANISM(S): Homo sapiens 
2013-08-26 | E-GEOD-48461 | biostudies-arrayexpress
TranscriptomicsMGMT-STP27 methylation status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951 [27K]
Purpose: The long-term follow-up results from the EORTC-26951 trial showed that the addition of PCV after radiotherapy increases survival in anaplastic oligodendrogliomas/oligoastrocytomas (AOD/AOA). However, some patients appeared to benefit more from PCV treatment than others. Experimental Design...
ORGANISM(S): Homo sapiens 
2013-08-26 | E-GEOD-48460 | biostudies-arrayexpress
Genomicsena-DATASET-ErasmusMC-30-07-2021-14:00:05:691-768 - samples
Intellance-2: TruSight Tumor 170 panel based DNA-seq
EGAD00001007945 | EGA
Genomicsena-DATASET-ErasmusMC-30-07-2021-13:54:47:012-763 - samples
Intellance-2: rRNA-minus RNA-seq
EGAD00001007943 | EGA
Genomicsena-DATASET-ErasmusMC-30-07-2021-13:58:26:615-766 - samples
Intellance-2: TruSight Tumor 170 panel based RNA-seq
EGAD00001007944 | EGA
GenomicsIntellance-2: omics data on recurrent glioblastoma patients participating in the Intellance-2 clinical trial, prior to treatment.
This study contains omics data from patients from the Intellance-2 clinical trial, in which effectiveness of ABT414 in EGFR amplified recurrent glioblastoma patients was tested. Patients were randomly assigned to one of three arms: (1) standard of care treatement (TMZ or CCNU), (2) Only ABT414 and (...
EGAS00001005437 | EGA
Genomicsena-DATASET-ErasmusMC-13-07-2021-14:23:08:540-67 - samples
Collection of mostly matching primary and recurrent glioblastoma RNA-seq sample pairs, also matching with an earlier DNA sequencing study
EGAD00001007860 | EGA
Sort   by:  
 Page size